Long-Term Outcomes of Analogue Insulin Compared With NPH for Patients With Type 2 Diabetes Mellitus
April 15th 2015There were no significant differences in the risk of ambulatory care—sensitive condition hospitalization or mortality between patients who initiated analogue insulin compared with the neutral protamine Hagedorn.
Read More
Assessing the Chiral Switch: Approval and Use of Single-Enantiomer Drugs, 2001 to 2011
March 14th 2014From 2001 to 2011, the US Food and Drug Administration approved 9 single-enantiomer drugs with racemic precursors. None showed pre-approval evidence of improved efficacy over the racemic precursor.
Read More